{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061514","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.410590+00:00","generated_at":"2026-06-08T06:40:13.260513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CalciMedica Q3 net loss $4.6M; Auxora reduces hospital days 53% in AIPT trial","bullets":["Net loss of $4.6M ($0.82/share) for Q3; cash $14.6M expected to fund through Q3 2024.","Auxora Phase 1/2 CRSPA in AIPT: 53% reduction in hospital days, 40% ICU days, eliminated TPN vs 27 days historical control. Data at ASH Dec 2023.","Phase 2b CARPO in acute pancreatitis with SIRS enrolling internationally; topline data H1 2024.","Preparing IND for Auxora in acute kidney injury; Phase 2 could start H1 2024 subject to funding.","Operating expenses $4.8M Q3; nine-month net loss $30.2M includes one-time merger charges."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061514","json":"https://secwatch.observer/filing/0000950170-23-061514.json","markdown":"https://secwatch.observer/filing/0000950170-23-061514.md","text":"https://secwatch.observer/filing/0000950170-23-061514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/0000950170-23-061514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/calc-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:40:13.260513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b245dc0629680127fcc4fe87a2c569b7d75b5766","claim":"CalciMedica, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $4.6 million, or $0.82 per share (basic and diluted), EPS $0.82 per share (basic and diluted).","evidence_excerpt":"CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/0000950170-23-061514-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $4.6 million, or $0.82 per share (basic and diluted)"},{"label":"EPS","value":"$0.82 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}